Search Results

Adocia, Allecra Therapeutics and Aldeyra Therapeutics announced promising results in Type I Diabetes, urinary tract infections and retinal diseases.

Adocia, a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced its fourth quarter financial results.

Adocia, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced the completion of the sale of its laboratory and office complex located in Lyon, France to a specialized investor.

Adocia announced that Gerard Soula, Adocia’s CEO, will be presenting at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 to 15, 2021.

Adocia announced that its partner Tonghua Dongbao Pharmaceutical Co. Ltd. received clearance from the Center for Drug Evaluation of the China National Medical Products Administration to conduct the Phase 3 clinical trial of BioChaperone® Lispro, an Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes.

ADOCIA announced Adocia will have an oral presentation on the bi-hormonal treatment M1Pram at the 81st Scientific Sessions of the American Diabetes Association which will be held June 25-29, 2021, as a virtual event.

Adocia (Euronext Paris: FR0011184241 – ADOC), announced today the launch of a Phase 1 clinical study in collaboration with Dr. Ahmad Haidar, McGill University, Canada, to assess pharmacokinetic, glycemic control and safety of BioChaperone® Lispro Pramlintide (BC LisPram) prandial formulation in 16 people with type 1 diabetes compared to rapid insulin lispro.

ADOCIA (Euronext Paris: FR0011184241 – ADOC the “Company”and “Adocia”), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today its financial results, including revenue and cash position, for the quarter ended March 31st, 2020.

Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.

Adocia announced that the American Arbitration Association Tribunal governing Adocia’s arbitration claims against Eli Lilly & Company dismissed both parties’ claims in the second and final phase of the arbitration between Adocia and Lilly.